Audrey Wang was so burned out from her job in high-end estate management that she broke out in hives that lasted six years.

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad ...

EXCLUSIVE: Kirsten Evans suffers a severe reaction to cold exposure that makes every winter a living nightmare ...

Patients with chronic spontaneous urticaria who respond rapidly to omalizumab show longer treatment persistence and require ...

Adults with moderate to severe chronic spontaneous urticaria who received once-daily 75 mg povorcitinib for 12 weeks had a ...

Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved ...

Sanofi ( SNY) and Regeneron’s ( REGN) Dupixent has gained EU approval as the first targeted therapy in more than ten years ...

As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works best has gained importance.

Patients with chronic spontaneous urticaria (CSU) experienced improved quality of life and sleep when symptoms were mitigated ...

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

TA is a patient who first began experiencing wheals (pantal) during her high school years. She recalls these episodes as ...

Women with CSU experience a greater burden of disease than men, with greater predominance and worsening burden observed in midlife.